Holen Sie sich die Stockscreener-App
3.625
4.01%
0.135
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt FBIO?
Forum
Prognose
Aktiensplit
Fortress Biotech Inc Aktie (FBIO) Neueste Nachrichten
Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving AverageWhat's Next? - MarketBeat
Wall Street Recap: How do insiders feel about Fortress Biotech IncDividend Hike & Trade Opportunity Analysis - baoquankhu1.vn
Exit Recap: Is Fortress Biotech Inc part of any ETFPortfolio Performance Summary & Long Hold Capital Preservation Tips - baoquankhu1.vn
Fortress Biotech, Inc. (NASDAQ:FBIO) Might Not Be As Mispriced As It Looks After Plunging 28% - 富途牛牛
Market Cool On Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Pushing Shares 28% Lower - simplywall.st
Fortress Biotech (NASDAQ:FBIO) Shares Jump Above Average Bulls Prepare For Follow Through - Kalkine Media
Fortress Biotech (NASDAQ:FBIO) Shares Pass Above 200-Day Moving AverageWhat's Next? - MarketBeat
Fortress Biotech amends credit agreement with Oaktree - MSN
(FBIOP) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Fortress Biotech (NASDAQ:FBIOP) Shares Down 4.7% – What’s Next? - Defense World
Fortress Biotech Leads High-Performing Stocks with 93.1% Return - Markets Mojo
Aug Technicals: Can Fortress Biotech Inc deliver alpha2025 Growth vs Value & Weekly Momentum Picks - baoquankhu1.vn
Fortress Biotech (NASDAQ:FBIO) Stock Price Crosses Above 200 Day Moving AverageHere's What Happened - MarketBeat
Fortress Biotech (NASDAQ:FBIO) Stock Price Crosses Above 200 Day Moving Average – Here’s What Happened - Defense World
ETF Watch: How liquid is OS Therapies Incorporated stockIPO Watch & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
How (FBIOP) Movements Inform Risk Allocation Models - Stock Traders Daily
Fortress Biotech, Inc. (NASDAQ:FBIO) Could Be Less Than A Year Away From Profitability - Yahoo Finance
Zacks Research Upgrades Fortress Biotech (NASDAQ:FBIO) to Strong-Buy - MarketBeat
Analysts Issue Forecasts for FBIO FY2025 Earnings - Defense World
Fortress Bio gains on FDA approval of copper replacement therapy - MSN
Research Analysts Set Expectations for FBIO FY2025 Earnings - MarketBeat
FBIO Stock Surges 12% Pre-Market After It Wins FDA Approval For Rare Pediatric Menkes Disease - Stocktwits
Risk Hedge: What are the risks of holding Fortress Biotech IncGap Down & Low Risk Entry Point Guides - baoquankhu1.vn
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO, the First and Only Approved Treatment for Menkes Disease in the United States - marketscreener.com
US FDA approves Fortress Bio and Zydus’ treatment for a rare pediatric disease - whtc.com
Investors Purchase Large Volume of Fortress Biotech Call Options (NASDAQ:FBIO) - MarketBeat
Fortress Biotech (FBIO) Surges After FDA Approval for Zycubo - GuruFocus
US FDA approves Fortress Bio and Zydus' treatment for a rare pediatric disease - Reuters
Fortress Biotech Gains FDA Approval for Menkes Treatment - TipRanks
Fortress Bio wins FDA nod for Menkes disease drug (FBIO:NASDAQ) - Seeking Alpha
Fortress Biotech and Cyprium Therapeutics Announce U.S. Fda Approval of Zycubo - marketscreener.com
FDA Approves Fortress Biotech's ZYCUBO for Pediatric Menkes Dise - GuruFocus
Fortress Biotech, Cyprium Say FDA Approved Zycubo for Pediatric Patients of Menkes Disease; Shares Rise Pre-Bell - marketscreener.com
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States - The Manila Times
Fortress Biotech and Cyprium Therapeutics Announce FDA Approval of ZYCUBO for Menkes Disease and Transfer of Rare Pediatric Disease Priority Review Voucher from Sentynl Therapeutics - Quiver Quantitative
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA - GlobeNewswire
Fortress Biotech's Subsidiary Nears Key FDA Decision, Shares Rise 3% - Intellectia AI
Trading Systems Reacting to (FBIOP) Volatility - Stock Traders Daily
Fortress Biotech (NASDAQ:FBIOP) Shares Up 2.4% – Should You Buy? - Defense World
Will Fortress Biotech Inc.(CNB0) stock rise with strong economyMarket Sentiment Summary & Risk Managed Investment Signals - Улправда
Fortress Biotech (NASDAQ:FBIO) Stock Price Crosses Above 200 Day Moving Average – What’s Next? - Defense World
Aug Rallies: Can Fortress Biotech Inc. stock hit record highs againBond Market & AI Optimized Trade Strategies - Улправда
Will Fortress Biotech Inc. stock benefit from AI adoptionOptions Play & Short-Term Trading Alerts - ulpravda.ru
Can Fortress Biotech Inc. stock hit record highs againMarket Movement Recap & Daily Profit Maximizing Tips - Улправда
How Fortress Biotech Inc. stock compares to industry benchmarksJobs Report & Real-Time Buy Signal Alerts - ulpravda.ru
Will Fortress Biotech Inc. stock outperform international peersJuly 2025 Review & Expert Verified Stock Movement Alerts - Улправда
Is Fortress Biotech Inc.(CNB0) stock testing key supportWeekly Investment Report & Stepwise Entry/Exit Trade Alerts - Улправда
Fortress Biotech (NASDAQ: FBIO) reports 13.4% Avenue (ATXI) stake with voting control - Stock Titan
Avenue Therapeutics | 4: Statement of changes in beneficial ownership of securities-10% Owner Fortress Biotech, Inc. - 富途牛牛
Head-To-Head Comparison: Fortress Biotech (NASDAQ:FBIO) & WAVE Life Sciences (NASDAQ:WVE) - Defense World
Avenue Therapeutics Provides Regulatory Update on IV Tramadol and Other Corporate Updates - ADVFN
Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults - ADVFN
Fortress Biotech (NASDAQ:FBIO) Stock Price Passes Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
0.24%
2.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):